Neutrophil inhibitory factor-hirulog hybrid

Drug Profile

Neutrophil inhibitory factor-hirulog hybrid

Alternative Names: rNIF-hirulog; TNHH

Latest Information Update: 28 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chongqing Fagen Biopharmaceutical
  • Developer Chongqing Fagen Biopharmaceutical; West China Hospital Sichuan University
  • Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action CD11b antigen modulators; CD18 antigen modulators; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Stroke

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top